Etoposide
VP-16
treatment
solid tumors
hematologic malignancies
high doses
conjunction
autologous bone marrow transplantation
agent
activity
treatment-resistant cancers
malignant glioma
patients
treated
recurrent
resistant
glioma
sudden severe
neurologic deterioration
days
initiation
high-dose etoposide therapy
clinical manifestations
confusion
papilledema
somnolence
exacerbation
motor deficits
increase
seizure
activity
abnormalities
initiation
high-dose
intravenous
patients
computerized tomographic (
CT
brain scans
stability
tumor size
peritumor edema
pretransplant scans
complication
toxicity
high-dose etoposide therapy
malignant glioma
